Developer docs
API playgroundTry for free, no card

Search company profiles

Cellumed

Full company profile

uuid003js71

Namestring
Cellumed
Legal namestring
(주)셀루메드
Websiteurl
cellumed.co.kr
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Cellumed is a Korean biotechnology and medical device company headquartered in Seoul, South Korea, that develops and manufactures musculoskeletal medical devices, tissue-engineered products, and biopharmaceutical manufacturing inputs. Its core product portfolio includes bone graft materials (Bio BMP2 recombinant human bone morphogenetic protein-2 coated on demineralized bone matrix, and Rafugen DBM demineralized bone matrix with US FDA approval since 2018), acellular dermal matrix products under the CELLUDERM brand (HD Implant, FILL, GEN, ULTRA, POWER variants) for breast reconstruction, plastic surgery, urology, and orthopedic applications, mRNA production enzymes under the CLnZyme brand (T7 RNA polymerase, DNase I, Pyrophosphatase), patient-specific surgical instruments (PSI) and AI-integrated surgical robot software, and recombinant growth factors (TGF-β1, FGF7) for cosmetic and medical applications.

Cellumed's business model is primarily one-time product sales (hardware) to hospitals, dental clinics, and pharmaceutical companies through direct enterprise sales and channel partnerships. The company employs an enterprise field sales motion targeting major Korean university hospitals (securing hospital codes at 14 major institutions for CELLUDERM breast reconstruction products) and uses distribution partners for specific product lines including Renew Medical (minimum 70 billion KRW annual dental powder supply agreement), Ezen Implant (ODM), and Ostem Implant (OEM for China distribution). The company also serves pharmaceutical companies with mRNA enzymes, including a partnership with Ijin for mRNA vaccine development. Cellumed holds multiple regulatory approvals including US FDA (Rafugen DBM, 2018), Taiwan FDA, Thailand FDA for BMP2, and ISO 13485 recertification (2025), enabling international market access.

Cellumed's consolidated operations include subsidiary Environment E&J (Hwangyeong Engineering), a construction company specializing in mechanical and fire protection equipment installation that contributes approximately 1 trillion KRW in annual revenue to consolidated financials. The company is listed on KOSDAQ (ticker 049180) and faces significant going concern issues following a 2025 fiscal year audit opinion rejection (issued April 2026) over subsidiary loan documentation and US lawsuit settlement liability concerns, triggering stock trading suspension and Korea Exchange delisting review. The company's largest shareholder changed in early 2026 through a 170 billion KRW rights offering to TD Landmark Union 1, which has signaled intent for management normalization and non-core asset divestiture.

Short descriptiontext

Cellumed is a Korean biotech and medical device company developing bone graft materials (Rafugen DBM, Bio BMP2), acellular dermal matrix products (CELLUDERM), mRNA production enzymes (CLnZyme), and AI-integrated surgical robotics for hospitals, dental clinics, and pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bone graft materials, tissue engineered products, mRNA production enzymes, acellular dermal matrix, orthopedic medical devices
Industry4 codes
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Dental Equipment and Supplies Manufacturing339114
SIC code3 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
  • Biological Products, (No Disgnostic Substances)2836
Product category
Orthopedic and Tissue Engineering Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Medical Devices (Bone Graft Materials)
TypeHardware Sales
Description

Sale of bone graft materials including Rafugen DBM, Bio BMP2, and dental bone graft products. These are one-time product sales for surgical procedures in orthopedics and dentistry.

cellumed.co.kr
2Tissue Bank Products
TypeHardware Sales
Description

Human tissue-based products including acellular dermal matrix (CELLUDERM series) for reconstructive surgeries. One-time product sales with recurring demand from surgical procedures.

cellumed.co.kr
3mRNA Production Enzymes
TypeHardware Sales
Description

Supply of GMP-grade mRNA production enzymes (CLnZyme brand) to pharmaceutical companies for mRNA vaccine and therapeutic development. Includes sample supply and long-term supply agreements.

cellumed.co.kr
4Cosmeceutical Products
TypeHardware Sales
Description

Bioactive cosmetic ingredients and products containing growth factors (FGF7, TGF-β1) supplied to parent company Insco Bio and through various distribution channels.

cellumed.co.kr
5Construction (Subsidiary Environment E&J)
TypeHardware Sales
Description

Construction subsidiary revenue from facility and equipment installation projects for large commercial and residential developments. Significant contribution to consolidated revenue.

cellumed.co.kr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Others
Pricing details1 tier
1B2B institutional pricing for medical facilities
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing negotiated through direct contracts with hospitals, university hospitals, and clinic chains. No public pricing available.

cellumed.co.kr
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1CELLUDERM
Description

Acellular dermal matrix (ADM) skin graft product line including HD Implant, FILL, GEN, ULTRA, and POWER variants for breast reconstruction and tissue regeneration

cellumed.co.kr
+6 more records
Core offering1 text field

Cellumed manufactures and sells bone graft materials (Bio BMP2 recombinant protein, Rafugen DBM demineralized bone matrix), acellular dermal matrix (CELLUDERM) skin graft products for reconstructive surgery, GMP-grade mRNA production enzymes under the CLnZyme brand, recombinant growth factors (TGF-β1, FGF7), and AI-integrated patient-specific surgical robotics for joint replacement. The company sells primarily to hospitals, dental clinics, and pharmaceutical companies in Korea and internationally, with manufacturing subsidiaries for biologics and construction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • BMP2 production yield improvement target: 5x increase through ATC+ government project
+2 more records
Product overview1 text field

Cellumed is a biotechnology and medical device company organized into multiple divisions spanning Tissue Bank, Medical Devices, mRNA Enzymes, Cosmeceuticals, and Electric Vehicles. Its core medical device portfolio centers on bone graft materials — including Bio BMP2 (rhBMP2-coated demineralized bone matrix), Rafugen DBM (FDA-approved bone graft), and Dental Powder — along with the CELLUDERM series of acellular dermal matrix (ADM) skin graft products (HD Implant, FILL, GEN, ULTRA, POWER). The company also develops AI-integrated surgical robotics combining PSI (patient-specific instrument) pre-planning with Cueresso's robotic system for joint replacement, and manufactures mRNA synthesis enzymes under the CLnZyme brand. Additional offerings include growth factors (TGF-β1, FGF7) for skincare, the BMG meniscus graft, and wellness products (ODF films). The Tissue Bank division processes human allografts, while the company has diversified into EV battery platforms via BYD partnership.

Product and service12 records
1Bio BMP2
CategoryBone Graft Material - Recombinant Protein
Description

Bone graft material combining demineralized bone matrix from donated human cadaveric bone coated with CHO-cell-derived recombinant human BMP2 (rhBMP2), mixed with sodium carboxymethyl cellulose and collagen gel from porcine skin. Used for alveolar bone defect filling to promote bone regeneration and preservation in orthopedic and dental procedures.

2Rafugen DBM (라퓨젠 DBM)
CategoryBone Graft Material - Demineralized Bone Matrix
Description

Demineralized bone matrix (DBM) bone graft material FDA-approved in 2018 for bone regeneration, also approved in Taiwan (2021) and Thailand. Uses a proprietary sterilization method (cold treatment before gamma irradiation) that preserves material physical properties while eliminating pathogens. Used for spinal fusion, orthopedic trauma, and bone defect filling.

3Dental Powder (덴탈 파우더)
CategoryBone Graft Material - Dental
Description

Human allogeneic bone graft material for dental implant procedures. Used to fill bone defects after tooth extraction and for socket preservation, bone ridge augmentation. Supplied to Renew Medical (under Renew Oss brand) and Ostem Implant as OEM, with a minimum 70 billion KRW annual supply contract with Renew Medical.

4CLnZyme (mRNA Production Enzymes)
CategorymRNA Biopharmaceutical Production Inputs
Description

mRNA synthesis enzyme brand producing key enzyme proteins for mRNA vaccine and therapeutic production, including T7 RNA polymerase, DNAse I, and Pyrophosphatase. Developed in partnership with German biotech Artes Biotechnology. 5 types of GMP-grade mRNA production enzymes supplied to pharmaceutical companies including Ijin.

5CELLUDERM HD Implant
CategoryAcellular Dermal Matrix - Skin Graft
Description

Acellular dermal matrix (ADM) skin graft product for breast reconstruction, soft tissue reconstruction, and burn treatment. Uses human dermis processed to remove immunogenic cells while preserving collagen and elastin ECM structure. Available in implant form.

6CELLUDERM FILL
CategoryAcellular Dermal Matrix - Injectable
Description

Injectable acellular dermal matrix (ADM) micropowder formulation mixed with purified water or biopolymer carrier. Available in 3cc and 8cc formats; designed for plastic surgery, breast surgery, orthopedics, and urology applications.

7CELLUDERM GEN / ULTRA / POWER Series
CategoryAcellular Dermal Matrix - Skin Graft Series
Description

Series of ADM-based skin graft products for various clinical indications including plastic surgery, urology, and orthopedics. Each variant (GEN, ULTRA, POWER) is tailored for specific surgical applications, with GEN positioned as next-generation injectable skin graft for therapeutic and cosmetic dual-use.

8Tissue Bank Services (조직 은행)
CategoryTissue Banking Services
Description

Processes donated human tissues into safe, high-quality allograft materials for transplantation. Develops tissue engineering products. KBB Tissue Bank holds US FDA registration (2007) and Korean MFDS tissue processing authorization (2006). Supplies allograft materials used across Cellumed's bone graft and dermal matrix product lines.

9PSI (Patient-Specific Instrument) + AI Surgical Robot System
CategoryAI-Integrated Surgical Robotics
Description

Patient-specific pre-operative surgical planning and AI-integrated robotic surgery assistance. Combines CT scan-based 3D anatomical reconstruction, biomechanical analysis, and Curexso's Qubeis-Joint robotic surgical system for artificial joint replacement. 4 patents registered in AI surgery design domain. Used at major Korean hospitals including Seoul National University Hospital, Severance Hospital, and Jeju University Hospital with over 700 successful surgeries.

10BMG (Bio Meniscus Graft)
CategoryOrthopedic Implant - Meniscus Graft
Description

Knee meniscus partial replacement graft — Korea's first MFDS-approved product. Clinical sites include Kyunghee Medical Center, Hanyang University Medical Center, and Samsung Seoul Hospital. Used for knee meniscus repair and replacement procedures.

11TGF-β1 / FGF7 Growth Factors
CategoryRecombinant Growth Factor Proteins
Description

Recombinant growth factor proteins developed for skincare and medical applications. TGF-β1 (transforming growth factor beta 1) is DNA-sequence-matched 100% to human skin and used for anti-aging, wound healing, and scar treatment. FGF7 (fibroblast growth factor 7) supports skin cell regeneration. Mass-produced after 10 years of government research.

12Proteoglycan Gwan-jil Kwang-kwang (ODF Health Functional Food)
CategoryWellness - Health Functional Food
Description

Oral dissolving film (ODF) health functional food containing 527mg of proteoglycan, chondroitin, and glutathione per film. Targets joint health and wellness market with sublingual absorption for high bioavailability.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-10-17
Description

Joint development of pancreatic cancer and idiopathic pulmonary fibrosis therapeutics using RNA-LNP technology.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2024-07-03
Description

Strategic partnership with Seoul National University Hospital Professor Noh Do-hyun's startup for AI and big data-based 3D joint surgery pre-planning system and 3rd generation surgical robot R&D.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-11-16
Description

Dental powder supply agreement with minimum 70 billion KRW annually. Cellumed supplies dental bone graft materials for distribution under Renew Medical's brand.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2022-10-27
Description

Strategic partnership for AI and big data-based imaging analysis systems. Integration of Gaion's gSmartVision AI technology with Cellumed's PSI and surgical robot software for enhanced preoperative planning.

5Curexso (큐렉소)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-10-04
Description

Surgical robot software development partnership. Curexso's Qubeis-Joint robot integrated with Cellumed's fixed-type and mobile-type artificial joints for robotic surgery system. FDA registration target for US market.

cellumed.co.kr
6Shenzhen Alpha Biotechnology
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-09-01
Description

MOU for mRNA production enzyme supply and joint R&D for China market entry. Shenzhen-based biotech specializing in vaccines and pharmaceuticals.

cellumed.co.kr
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-10-13
Description

Contract development and technology transfer for mRNA production enzyme development. German biotech company providing process development for GMP-grade enzyme production. 2 types of mRNA production enzymes under joint development.

8Yejin Pharma (이연제약)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-09-28
Description

MOU for GMP mass production of 5 types of mRNA production enzymes and joint R&D for mRNA-based vaccines and therapeutics using Cheongju bio facility.

cellumed.co.kr
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-07-22
Description

Joint research for cervical cancer HPV antibody diagnostic and vaccine development. Plant-based recombinant protein platform using Professor Hwang In-hwan's green vaccine technology.

10Ijin (아이진)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-08
Description

Main contract for mRNA-based vaccine and anticancer drug development. Cellumed developing 5 types of mRNA production enzymes for supply to Ijin. Joint development of COVID-19 mRNA vaccine with technology transfer and mass production process development.

cellumed.co.kr
11Chungnam Geumsan County (충남 금산군)
Strategic tierMinorTypeOthersAnnounced on2019-09-03
Description

Medical welfare support MOU providing medical examinations and surgeries for economically disadvantaged residents aged 65+ in Geumsan county.

cellumed.co.kr
12Major Korean University Hospitals
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research partnerships with Seoul National University Hospital, Severance Hospital, Jeju University Hospital, Myeongji Hospital for PSI knee replacement procedures. Over 700 surgical cases completed.

cellumed.co.kr
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

DBM dental bone graft products supplied under OEM arrangement. China's leading dental implant company distributing Cellumed products.

14Environment E&J (환경이엔지) - Subsidiary
Strategic tierCoreTypeOthers
Description

Construction subsidiary specializing in mechanical and fire protection equipment installation. Major construction company partnerships including 1-tier builders. Revenue contribution to consolidated financials.

cellumed.co.kr
Strategic tierMajorTypeTechnology or Integration
Description

T7 RNA polymerase performance evaluation conducted by Korea's largest testing and certification institute for quality validation and certification of mRNA enzyme products.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US regenerative medicine company specializing in advanced wound care and skin substitutes (Apligraf, Dermagraft). Direct peer to Cellumed's CELLUDERM acellular dermal matrix product line serving similar plastic surgery, wound healing, and reconstructive applications.

TypeDirect peer
Description

US-based manufacturer of high-quality plasmid DNA, mRNA, and proteins for biotech and pharmaceutical customers. Direct peer to Cellumed's CLnZyme mRNA production enzyme business, serving the same mRNA vaccine and therapeutic developer customer base.

TypeDirect peer
Description

Global medical device leader whose INFUSE Bone Graft (rhBMP2) product directly competes with Cellumed's Bio BMP2 in the bone graft substitute market. Medtronic is the dominant commercial BMP2 supplier globally and serves as the primary benchmark for Cellumed's BMP2 ambitions.

TypeBroad incumbent
Description

Global orthopedic medical device leader offering joint replacement, trauma, and surgical navigation systems. Broad incumbent competitor to Cellumed's orthopedic bone graft and PSI surgical instrument offerings, though Stryker operates at much greater scale across multiple orthopedic segments.

TypeDirect peer
Description

US company specializing in placental tissue allografts and regenerative medicine products. Comparable to Cellumed through its focus on allograft tissue processing for wound healing, surgical recovery, and tissue regeneration applications.

TypeRegional player
Description

Korean biotech company specializing in stem cell therapy and regenerative medicine products including cell therapy for cartilage regeneration. Comparable to Cellumed through its Korean market presence and focus on musculoskeletal/cartilage regenerative medicine applications.

TypeDirect peer
Description

Non-profit organ procurement and tissue banking organization providing allograft tissue for orthopedic, spine, and reconstructive surgery. Direct competitor to Cellumed's tissue bank division with similar allograft product offerings for bone regeneration.

TypeDirect peer
Description

Non-profit tissue bank and regenerative medicine organization that processes donated human allograft tissue for surgical use, mirroring Cellumed's KBB Tissue Bank operations. Direct peer in the allograft tissue processing and distribution segment.

TypeDirect peer
Description

US medical device company specializing in orthopedic biologics, dural repair, and regenerative tissue products. Comparable to Cellumed through its allograft/demineralized bone matrix portfolio and similar focus on surgical reconstruction applications.

10Corestem
TypeRegional player
Description

Korean biotech company developing stem cell therapies for autoimmune and degenerative diseases including chondrogenic applications. Regional peer to Cellumed in Korean regenerative medicine market with overlapping musculoskeletal and cartilage-focused research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellumed

Orthopedic and Tissue Engineering Medical Devicescellumed.co.kr

Cellumed is a Korean biotech and medical device company developing bone graft materials (Rafugen DBM, Bio BMP2), acellular dermal matrix products (CELLUDERM), mRNA production enzymes (CLnZyme), and AI-integrated surgical robotics for hospitals, dental clinics, and pharmaceutical companies.

What Cellumed does

Cellumed is a Korean biotechnology and medical device company headquartered in Seoul, South Korea, that develops and manufactures musculoskeletal medical devices, tissue-engineered products, and biopharmaceutical manufacturing inputs. Its core product portfolio includes bone graft materials (Bio BMP2 recombinant human bone morphogenetic protein-2 coated on demineralized bone matrix, and Rafugen DBM demineralized bone matrix with US FDA approval since 2018), acellular dermal matrix products under the CELLUDERM brand (HD Implant, FILL, GEN, ULTRA, POWER variants) for breast reconstruction, plastic surgery, urology, and orthopedic applications, mRNA production enzymes under the CLnZyme brand (T7 RNA polymerase, DNase I, Pyrophosphatase), patient-specific surgical instruments (PSI) and AI-integrated surgical robot software, and recombinant growth factors (TGF-β1, FGF7) for cosmetic and medical applications.

Cellumed's business model is primarily one-time product sales (hardware) to hospitals, dental clinics, and pharmaceutical companies through direct enterprise sales and channel partnerships. The company employs an enterprise field sales motion targeting major Korean university hospitals (securing hospital codes at 14 major institutions for CELLUDERM breast reconstruction products) and uses distribution partners for specific product lines including Renew Medical (minimum 70 billion KRW annual dental powder supply agreement), Ezen Implant (ODM), and Ostem Implant (OEM for China distribution). The company also serves pharmaceutical companies with mRNA enzymes, including a partnership with Ijin for mRNA vaccine development. Cellumed holds multiple regulatory approvals including US FDA (Rafugen DBM, 2018), Taiwan FDA, Thailand FDA for BMP2, and ISO 13485 recertification (2025), enabling international market access.

Cellumed's consolidated operations include subsidiary Environment E&J (Hwangyeong Engineering), a construction company specializing in mechanical and fire protection equipment installation that contributes approximately 1 trillion KRW in annual revenue to consolidated financials. The company is listed on KOSDAQ (ticker 049180) and faces significant going concern issues following a 2025 fiscal year audit opinion rejection (issued April 2026) over subsidiary loan documentation and US lawsuit settlement liability concerns, triggering stock trading suspension and Korea Exchange delisting review. The company's largest shareholder changed in early 2026 through a 170 billion KRW rights offering to TD Landmark Union 1, which has signaled intent for management normalization and non-core asset divestiture.

Cellumed firmographics

Firmographics
Name
Cellumed
Legal name
(주)셀루메드
Website
https://cellumed.co.kr
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
Cellumed is a Korean biotech and medical device company developing bone graft materials (Rafugen DBM, Bio BMP2), acellular dermal matrix products (CELLUDERM), mRNA production enzymes (CLnZyme), and AI-integrated surgical robotics for hospitals, dental clinics, and pharmaceutical companies.
Ownership category
akta.pro rank

Cellumed industry classification

Industry
Product category
Orthopedic and Tissue Engineering Medical Devices
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Dental Equipment and Supplies Manufacturing (339114)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Bone graft materials
  • Tissue engineered products
  • MRNA production enzymes
  • Acellular dermal matrix
  • Orthopedic medical devices

Where Cellumed is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Cellumed business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Medical Devices (Bone Graft Materials): Sale of bone graft materials including Rafugen DBM, Bio BMP2, and dental bone graft products. These are one-time product sales for surgical procedures in orthopedics and dentistry.
  2. Tissue Bank Products: Human tissue-based products including acellular dermal matrix (CELLUDERM series) for reconstructive surgeries. One-time product sales with recurring demand from surgical procedures.
  3. mRNA Production Enzymes: Supply of GMP-grade mRNA production enzymes (CLnZyme brand) to pharmaceutical companies for mRNA vaccine and therapeutic development. Includes sample supply and long-term supply agreements.
  4. Cosmeceutical Products: Bioactive cosmetic ingredients and products containing growth factors (FGF7, TGF-β1) supplied to parent company Insco Bio and through various distribution channels.
  5. Construction (Subsidiary Environment E&J): Construction subsidiary revenue from facility and equipment installation projects for large commercial and residential developments. Significant contribution to consolidated revenue.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B institutional pricing for medical facilities

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Cellumed product offering

Product offering

Core offering

Cellumed manufactures and sells bone graft materials (Bio BMP2 recombinant protein, Rafugen DBM demineralized bone matrix), acellular dermal matrix (CELLUDERM) skin graft products for reconstructive surgery, GMP-grade mRNA production enzymes under the CLnZyme brand, recombinant growth factors (TGF-β1, FGF7), and AI-integrated patient-specific surgical robotics for joint replacement. The company sells primarily to hospitals, dental clinics, and pharmaceutical companies in Korea and internationally, with manufacturing subsidiaries for biologics and construction.

Product overview

Cellumed is a biotechnology and medical device company organized into multiple divisions spanning Tissue Bank, Medical Devices, mRNA Enzymes, Cosmeceuticals, and Electric Vehicles. Its core medical device portfolio centers on bone graft materials — including Bio BMP2 (rhBMP2-coated demineralized bone matrix), Rafugen DBM (FDA-approved bone graft), and Dental Powder — along with the CELLUDERM series of acellular dermal matrix (ADM) skin graft products (HD Implant, FILL, GEN, ULTRA, POWER). The company also develops AI-integrated surgical robotics combining PSI (patient-specific instrument) pre-planning with Cueresso's robotic system for joint replacement, and manufactures mRNA synthesis enzymes under the CLnZyme brand. Additional offerings include growth factors (TGF-β1, FGF7) for skincare, the BMG meniscus graft, and wellness products (ODF films). The Tissue Bank division processes human allografts, while the company has diversified into EV battery platforms via BYD partnership.

Differentiator

Problem solved

Functional benefit

Brands

  • CELLUDERM: Acellular dermal matrix (ADM) skin graft product line including HD Implant, FILL, GEN, ULTRA, and POWER variants for breast reconstruction and tissue regeneration
  • Rafugen DBM
  • Bio BMP2
  • CLnZyme
  • Lapugen
  • BMG (Bio Meniscus Graft)
  • Viscoil

Products and services

  • Bio BMP2 Bone graft material combining demineralized bone matrix from donated human cadaveric bone coated with CHO-cell-derived recombinant human BMP2 (rhBMP2), mixed with sodium carboxymethyl cellulose and collagen gel from porcine skin. Used for alveolar bone defect filling to promote bone regeneration and preservation in orthopedic and dental procedures.
  • Rafugen DBM (라퓨젠 DBM) Demineralized bone matrix (DBM) bone graft material FDA-approved in 2018 for bone regeneration, also approved in Taiwan (2021) and Thailand. Uses a proprietary sterilization method (cold treatment before gamma irradiation) that preserves material physical properties while eliminating pathogens. Used for spinal fusion, orthopedic trauma, and bone defect filling.
  • Dental Powder (덴탈 파우더) Human allogeneic bone graft material for dental implant procedures. Used to fill bone defects after tooth extraction and for socket preservation, bone ridge augmentation. Supplied to Renew Medical (under Renew Oss brand) and Ostem Implant as OEM, with a minimum 70 billion KRW annual supply contract with Renew Medical.
  • CLnZyme (mRNA Production Enzymes) mRNA synthesis enzyme brand producing key enzyme proteins for mRNA vaccine and therapeutic production, including T7 RNA polymerase, DNAse I, and Pyrophosphatase. Developed in partnership with German biotech Artes Biotechnology. 5 types of GMP-grade mRNA production enzymes supplied to pharmaceutical companies including Ijin.
  • CELLUDERM HD Implant Acellular dermal matrix (ADM) skin graft product for breast reconstruction, soft tissue reconstruction, and burn treatment. Uses human dermis processed to remove immunogenic cells while preserving collagen and elastin ECM structure. Available in implant form.
  • CELLUDERM FILL Injectable acellular dermal matrix (ADM) micropowder formulation mixed with purified water or biopolymer carrier. Available in 3cc and 8cc formats; designed for plastic surgery, breast surgery, orthopedics, and urology applications.
  • CELLUDERM GEN / ULTRA / POWER Series Series of ADM-based skin graft products for various clinical indications including plastic surgery, urology, and orthopedics. Each variant (GEN, ULTRA, POWER) is tailored for specific surgical applications, with GEN positioned as next-generation injectable skin graft for therapeutic and cosmetic dual-use.
  • Tissue Bank Services (조직 은행) Processes donated human tissues into safe, high-quality allograft materials for transplantation. Develops tissue engineering products. KBB Tissue Bank holds US FDA registration (2007) and Korean MFDS tissue processing authorization (2006). Supplies allograft materials used across Cellumed's bone graft and dermal matrix product lines.
  • PSI (Patient-Specific Instrument) + AI Surgical Robot System Patient-specific pre-operative surgical planning and AI-integrated robotic surgery assistance. Combines CT scan-based 3D anatomical reconstruction, biomechanical analysis, and Curexso's Qubeis-Joint robotic surgical system for artificial joint replacement. 4 patents registered in AI surgery design domain. Used at major Korean hospitals including Seoul National University Hospital, Severance Hospital, and Jeju University Hospital with over 700 successful surgeries.
  • BMG (Bio Meniscus Graft) Knee meniscus partial replacement graft — Korea's first MFDS-approved product. Clinical sites include Kyunghee Medical Center, Hanyang University Medical Center, and Samsung Seoul Hospital. Used for knee meniscus repair and replacement procedures.
  • TGF-β1 / FGF7 Growth Factors Recombinant growth factor proteins developed for skincare and medical applications. TGF-β1 (transforming growth factor beta 1) is DNA-sequence-matched 100% to human skin and used for anti-aging, wound healing, and scar treatment. FGF7 (fibroblast growth factor 7) supports skin cell regeneration. Mass-produced after 10 years of government research.
  • Proteoglycan Gwan-jil Kwang-kwang (ODF Health Functional Food) Oral dissolving film (ODF) health functional food containing 527mg of proteoglycan, chondroitin, and glutathione per film. Targets joint health and wellness market with sublingual absorption for high bioavailability.

Quantifiable outcome

  • BMP2 production yield improvement target: 5x increase through ATC+ government project
  • +2 more outcomes

Companies that use Cellumed

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Cellumed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Cellumed partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered major, core and minor.

  • Seogang University (서강대)majorStrategic or Co-development Partner · 17 October 2024Joint development of pancreatic cancer and idiopathic pulmonary fibrosis therapeutics using RNA-LNP technology.
  • Cognitive (코넥티브)majorTechnology or Integration · 3 July 2024Strategic partnership with Seoul National University Hospital Professor Noh Do-hyun's startup for AI and big data-based 3D joint surgery pre-planning system and 3rd generation surgical robot R&D.
  • Renew Medical (리뉴메디칼)majorChannel Partner/ Reseller/ Distributor · 16 November 2023Dental powder supply agreement with minimum 70 billion KRW annually. Cellumed supplies dental bone graft materials for distribution under Renew Medical's brand.
  • Gaion (가이온)majorTechnology or Integration · 27 October 2022Strategic partnership for AI and big data-based imaging analysis systems. Integration of Gaion's gSmartVision AI technology with Cellumed's PSI and surgical robot software for enhanced preoperative planning.
  • Curexso (큐렉소)coreTechnology or Integration · 4 October 2022Surgical robot software development partnership. Curexso's Qubeis-Joint robot integrated with Cellumed's fixed-type and mobile-type artificial joints for robotic surgery system. FDA registration target for US market.
  • Shenzhen Alpha BiotechnologymajorStrategic or Co-development Partner · 1 September 2022MOU for mRNA production enzyme supply and joint R&D for China market entry. Shenzhen-based biotech specializing in vaccines and pharmaceuticals.
  • Artes Biotechnology (아르떼)coreTechnology or Integration · 13 October 2021Contract development and technology transfer for mRNA production enzyme development. German biotech company providing process development for GMP-grade enzyme production. 2 types of mRNA production enzymes under joint development.
  • Yejin Pharma (이연제약)majorStrategic or Co-development Partner · 28 September 2021MOU for GMP mass production of 5 types of mRNA production enzymes and joint R&D for mRNA-based vaccines and therapeutics using Cheongju bio facility.
  • Apimez (아피메즈) / Pohang UniversitymajorStrategic or Co-development Partner · 22 July 2021Joint research for cervical cancer HPV antibody diagnostic and vaccine development. Plant-based recombinant protein platform using Professor Hwang In-hwan's green vaccine technology.
  • Ijin (아이진)coreStrategic or Co-development Partner · 8 July 2021Main contract for mRNA-based vaccine and anticancer drug development. Cellumed developing 5 types of mRNA production enzymes for supply to Ijin. Joint development of COVID-19 mRNA vaccine with technology transfer and mass production process development.
  • Chungnam Geumsan County (충남 금산군)minorOthers · 3 September 2019Medical welfare support MOU providing medical examinations and surgeries for economically disadvantaged residents aged 65+ in Geumsan county.
  • Major Korean University HospitalscoreStrategic or Co-development PartnerClinical research partnerships with Seoul National University Hospital, Severance Hospital, Jeju University Hospital, Myeongji Hospital for PSI knee replacement procedures. Over 700 surgical cases completed.
  • Ostem Implant (오스템임플란트)majorChannel Partner/ Reseller/ DistributorDBM dental bone graft products supplied under OEM arrangement. China's leading dental implant company distributing Cellumed products.
  • Environment E&J (환경이엔지) - SubsidiarycoreOthersConstruction subsidiary specializing in mechanical and fire protection equipment installation. Major construction company partnerships including 1-tier builders. Revenue contribution to consolidated financials.
  • Korea Construction & Environment Research Institute (한국건설생활환경시험연구소)majorTechnology or IntegrationT7 RNA polymerase performance evaluation conducted by Korea's largest testing and certification institute for quality validation and certification of mRNA enzyme products.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Cellumed competitors and assessment

Company assessment

Direct peers

  • Organogenesis: US regenerative medicine company specializing in advanced wound care and skin substitutes (Apligraf, Dermagraft). Direct peer to Cellumed's CELLUDERM acellular dermal matrix product line serving similar plastic surgery, wound healing, and reconstructive applications.
  • Aldevron: US-based manufacturer of high-quality plasmid DNA, mRNA, and proteins for biotech and pharmaceutical customers. Direct peer to Cellumed's CLnZyme mRNA production enzyme business, serving the same mRNA vaccine and therapeutic developer customer base.
  • Medtronic: Global medical device leader whose INFUSE Bone Graft (rhBMP2) product directly competes with Cellumed's Bio BMP2 in the bone graft substitute market. Medtronic is the dominant commercial BMP2 supplier globally and serves as the primary benchmark for Cellumed's BMP2 ambitions.
  • MiMedx: US company specializing in placental tissue allografts and regenerative medicine products. Comparable to Cellumed through its focus on allograft tissue processing for wound healing, surgical recovery, and tissue regeneration applications.
  • LifeNet Health: Non-profit organ procurement and tissue banking organization providing allograft tissue for orthopedic, spine, and reconstructive surgery. Direct competitor to Cellumed's tissue bank division with similar allograft product offerings for bone regeneration.
  • MTF Biologics: Non-profit tissue bank and regenerative medicine organization that processes donated human allograft tissue for surgical use, mirroring Cellumed's KBB Tissue Bank operations. Direct peer in the allograft tissue processing and distribution segment.
  • Integra LifeSciences: US medical device company specializing in orthopedic biologics, dural repair, and regenerative tissue products. Comparable to Cellumed through its allograft/demineralized bone matrix portfolio and similar focus on surgical reconstruction applications.

Broad incumbents

  • Stryker: Global orthopedic medical device leader offering joint replacement, trauma, and surgical navigation systems. Broad incumbent competitor to Cellumed's orthopedic bone graft and PSI surgical instrument offerings, though Stryker operates at much greater scale across multiple orthopedic segments.

Regional players

  • Pharmicell: Korean biotech company specializing in stem cell therapy and regenerative medicine products including cell therapy for cartilage regeneration. Comparable to Cellumed through its Korean market presence and focus on musculoskeletal/cartilage regenerative medicine applications.
  • Corestem: Korean biotech company developing stem cell therapies for autoimmune and degenerative diseases including chondrogenic applications. Regional peer to Cellumed in Korean regenerative medicine market with overlapping musculoskeletal and cartilage-focused research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

Cellumed social profiles

Digital presence

Cellumed compliance and trust

Trust signal

Compliance3 records

Cellumed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellumed leadership team

Management profile

Number of profiles

Profiles4 records

Cellumed subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Cellumed funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellumed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellumed

What does Cellumed do?

Cellumed manufactures and sells bone graft materials (Bio BMP2 recombinant protein, Rafugen DBM demineralized bone matrix), acellular dermal matrix (CELLUDERM) skin graft products for reconstructive surgery, GMP-grade mRNA production enzymes under the CLnZyme brand, recombinant growth factors (TGF-β1, FGF7), and AI-integrated patient-specific surgical robotics for joint replacement. The company sells primarily to hospitals, dental clinics, and pharmaceutical companies in Korea and internationally, with manufacturing subsidiaries for biologics and construction.

Is Cellumed a public or private company?

Cellumed is a public company. It is classified as public and is currently operating.

When was Cellumed founded?

Cellumed was founded in 2005. It employs 1 to 10 people.

Where is Cellumed based?

Cellumed is headquartered in Seoul, South Korea, in the Asia region.

How does Cellumed make money?

Five revenue lines are on record. Medical Devices (Bone Graft Materials) is the primary driver. The others are tissue Bank Products, mRNA Production Enzymes, cosmeceutical Products and construction (Subsidiary Environment E&J).

Who are Cellumed's main competitors?

Direct peers on record are Organogenesis, Aldevron, Medtronic, MiMedx, LifeNet Health, MTF Biologics and Integra LifeSciences. Stryker is listed as a broad incumbent. Regional players are Pharmicell and Corestem.

Does Cellumed have an API?

No public API is recorded for Cellumed.

What industry is Cellumed in?

Cellumed's product category is Orthopedic and Tissue Engineering Medical Devices. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 325414 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals